Literatur
- 1
Jabs D A, Nussenblatt R B, Rosenbaum J T.
Standardization of uveitis nomenclature for reporting clinical data. Results of the
first international workshop.
Am J Ophthalmol.
2005;
140
509-516
- 2
Gritz D C, Wong I G.
Incidence and prevalence of uveitis in Northern California; the Northern California
Epidemiology of Uveitis Study.
Ophthalmology.
2004;
111
491-500
discussion
500
- 3
Smith J R, Mackensen F, Rosenbaum J T.
Therapy insight: scleritis and its relationship to systemic autoimmune disease.
Nat Clin Pract.
2007;
3
219-226
- 4
Haynes B F, Fishman M L, Fauci A S et al.
The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and
review of the literature.
Am J Med.
1977;
63
131-141
- 5
Dunne J A, Jacobs N, Morrison A et al.
Efficacy in anterior uveitis of two known steroids and topical tolmetin.
Br J Ophthalmol.
1985;
69
120-125
- 6
Sand B B, Krogh E.
Topical indometacin, a prostaglandin inhibitor, in acute anterior uveitis. A controlled
clinical trial of non-steroid versus steroid anti-inflammatory treatment.
Acta Ophthalmol (Copenh).
1991;
69
145-148
- 7
Weijtens O, Feron E J, Schoemaker R C et al.
High concentration of dexamethasone in aqueous and vitreous after subconjunctival
injection.
Am J Ophthalmol.
1999;
128
192-197
- 8
Weijtens O, Schoemaker R C, Romijn F P et al.
Intraocular penetration and systemic absorption after topical application of dexamethasone
disodium phosphate.
Ophthalmology.
2002;
109
1887-1891
- 9
Weijtens O, van der Sluijs F A, Schoemaker R C et al.
Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone
disodium phosphate injection.
Am J Ophthalmol.
1997;
123
358-363
- 10
Benitez-Del-Castillo J M, Garcia-Sanchez J, Iradier T et al.
Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis.
Eye (Lond).
2000;
14 (Pt 3A)
340-343
- 11
Hatemi G, Silman A, Bang D et al.
EULAR recommendations for the management of Behcet disease.
Annals of the Rheumatic Diseases.
2008;
67
1656-1662
- 12
Sfikakis P P, Markomichelakis N, Alpsoy E et al.
Anti-TNF therapy in the management of Behcet's disease – review and basis for recommendations.
Rheumatology (Oxford, England).
2007;
46
736-741
- 13
Alpsoy E, Durusoy C, Yilmaz E et al.
Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled
and double-blind study.
Archives of Dermatology.
2002;
138
467-471
- 14
Becker M D, Heiligenhaus A, Hudde T et al.
Interferon as a treatment for uveitis associated with multiple sclerosis.
Br J Ophthalmol.
2005;
89
1254-1257
- 15
Heiligenhaus A, Duck N, Michel D et al.
Indication and effect of immunosuppression in patients with scleritis.
Klin Monatsbl Augenheilkd.
2003;
220
471-480
- 16
Jabs D A, Mudun A, Dunn J P et al.
Episcleritis and scleritis: clinical features and treatment results.
Am J Ophthalmol.
2000;
130
469-476
- 17
Watson P G, Young R D.
Scleral structure, organisation and disease. A review.
Experimental Eye Research.
2004;
78
609-623
- 18
Bauer A M, Fiehn C, Becker M D.
Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior
scleritis.
Am J Ophthalmol.
2005;
139
1086-1089
- 19
Sainz de la Maza M, Jabbur N S, Foster C S.
An analysis of therapeutic decision for scleritis.
Ophthalmology.
1993;
100
1372-1376
- 20
Sen H N, Suhler E B, Al-Khatib S Q et al.
Mycophenolate mofetil for the treatment of scleritis.
Ophthalmology.
2003;
110
1750-1755
- 21
Soukiasian S H, Foster C S, Raizman M B.
Treatment strategies for scleritis and uveitis associated with inflammatory bowel
disease.
Am J Ophthalmol.
1994;
118
601-611
- 22
Wakefield D, McCluskey P.
Cyclosporin therapy for severe scleritis.
Br J Ophthalmol.
1989;
73
743-746
- 23
Taylor S R, Salama A D, Joshi L et al.
Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.
Arthritis and Rheumatism.
2009;
60
1540-1547
- 24
Doctor P, Sultan A, Syed S et al.
Infliximab for the treatment of refractory scleritis.
Br J Ophthalmology.
2010;
94 (5)
579-583
- 25
Meyer P A, Watson P G, Franks W et al.
‘Pulsed immunosuppressive therapy in the treatment of immunologically induced corneal
and scleral disease.
Eye.
1987;
1 (Pt 4)
487-495
- 26
Wessels J A, Huizinga T W, Guchelaar H J.
Recent insights in the pharmacological actions of methotrexate in the treatment of
rheumatoid arthritis.
Rheumatology.
2008;
47
249-255
- 27
Samson C M, Waheed N, Baltatzis S et al.
Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series
of 160 patients.
Ophthalmology.
2001;
108
1134-1139
- 28
van Ede A E, Laan R F, Rood M J et al.
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate
in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind,
placebo-controlled study.
Arthritis Rheum.
2001;
44
1515-1524
- 29
Gangaputra S, Newcomb C W, Liesegang T L et al.
Methotrexate for ocular inflammatory diseases.
Ophthalmology.
2009;
116
2188-2198
e2181
- 30
Hesselink D A, Baarsma G S, Kuijpers R W et al.
Experience with cyclosporine in endogenous uveitis posterior.
Transplant Proc.
2004;
36
372S-377S
- 31
Zierhut M, Stubiger N, Aboalchamat W et al.
Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis.
Ophthalmologe.
2001;
98
647-651
- 32
Baltatzis S, Tufail F, Yu E N et al.
Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular
inflammatory disorders.
Ophthalmology.
2003;
110
1061-1065
- 33
Daniel E, Thorne J E, Newcomb C W et al.
Mycophenolate mofetil for ocular inflammation.
Am J Ophthalmol.
2009;
149
423-432
e421-422
- 34
Pasadhika S, Kempen J H, Newcomb C W et al.
Azathioprine for ocular inflammatory diseases.
Am J Ophthalmol.
2009;
148
500-509
e502
- 35
Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J et al.
Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year
period.
J Rheumatol.
2003;
30
1277-1279
- 36
Pujari S S, Kempen J H, Newcomb C W et al.
Cyclophosphamide for ocular inflammatory diseases.
Ophthalmology.
2009;
117
356-365
- 37
Dick A D, Forrester J V, Liversidge J et al.
The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis
(EAU).
Progress in Retinal and Eye Research.
2004;
23
617-637
- 38
Diel R, Hauer B, Loddenkemper R et al.
Empfehlungen für das Tuberkulose-Screening vor Gabe von TNF-α-Inhibitoren bei rheumatischen
Erkrankungen.
Pneumologie.
2009;
63
329-334
- 39
Foster C S, Tufail F, Waheed N K et al.
Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate.
Archives of Ophthalmology.
2003;
121
437-440
- 40
Galor A, Perez V L, Hammel J P et al.
Differential effectiveness of etanercept and infliximab in the treatment of ocular
inflammation.
Ophthalmology.
2006;
113
2317-2323
- 41
Sieper J, Koenig A, Baumgartner S et al.
Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials.
Annals of the Rheumatic Diseases.
2010;
69
226-229
- 42
Diaz-Llopis M, Garcia-Delpech S, Salom D et al.
Adalimumab therapy for refractory uveitis: a pilot study.
J Ocul Pharmacol Ther.
2008;
24
351-361
- 43
Suhler E B, Smith J R, Giles T R et al.
Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.
Archives of Ophthalmology.
2009;
127
819-822
- 44
Suhler E B, Smith J R, Wertheim M S et al.
A prospective trial of infliximab therapy for refractory uveitis: preliminary safety
and efficacy outcomes.
Archives of Ophthalmology.
2005;
123
903-912
- 45
Tugal-Tutkun I, Mudun A, Urgancioglu M et al.
Efficacy of infliximab in the treatment of uveitis that is resistant to treatment
with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's
disease: an open-label trial.
Arthritis and Rheumatism.
2005;
52
2478-2484
- 46
Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M.
Results of interferon-alfa therapy in patients with Behcet uveitis.
Graefes Arch Clin Exp Ophthalmol.
2006;
244
1692-1695
- 47
Gueudry J, Wechsler B, Terrada C et al.
Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis
associated with Behcet disease.
Am J Ophthalmol.
2008;
146
837-844
e831
- 48
Deuter C M, Kotter I, Gunaydin I et al.
Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid
macular oedema due to non-infectious uveitis.
Br J Ophthalmol.
2009;
93
906-913
- 49
Sadreddini S, Noshad H, Molaeefard M et al.
Treatment of retinal vasculitis in Behcet's disease with rituximab.
Modern Rheumatology/The Japan Rheumatism Association.
2008;
18
306-308
- 50
Tappeiner C, Heinz C, Specker C et al.
Rituximab as a treatment option for refractory endogenous anterior uveitis.
Ophthalmic Research.
2007;
39
184-186
Dr. med. Carsten Heinz
Augenabteilung am St. Franziskus Hospital Münster
Hohenzollernring 74
48145 Münster
Email: carsten.heinz@uveitis-zentrum.de
